aracterize their patients’ tumors on a real-time basis by analyzing CTCs and ctDNA found in standard blood draws. The company’s approach is to develop and commercialize CTC and ctDNA tests and services to enable the company to offer to oncologists standard blood sample based, real-time, testing solutions for a range of solid tumor types, starting with breast cancer and progressing to future launches of tests for non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma and others, to improve patient treatment with better prognostic and predictive tools. Research and Development The company incurred research and development expenses of $3.1 million, as of December 31, 2013. Patents and Technology The company’s patent portfolio consists of three issued U.S. patents, six pending U.S. patent applications and corresponding foreign patents and foreign patent applications. These patents and patent applications are related to various aspects of its and planned CTC and ctDNA tests, including its CEE microfluidic channels, its CEE-Sure blood collection tubes, CEE-Cap antibody capture cocktail, CEE-Enhanced staining methodology, and CEE-Selector technology for mutation detection. Sales and Marketing The company’s sales and marketing activities consist of working with its partners and establishing its own direct sales force in the United States focused on selling directly to community oncologists in hospitals, cancer centers and offices, as well as biopharma companies and supporting its partners as technical specialists and medical science liaisons. Significant Events In October 2014, Biocept, Inc. announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer. In October 2014, Biocept, Inc. and Rosetta Genomics, Ltd. announced a collaboration that would combine both companies' platform technologies in an innovative approach to cancer diagnostics. In January 2015, Biocept, Inc. and Insight Genetics announced their collaboration to generate an enhanced diagnostic for the expression and mutation of ALK, a major therapeutic target in the treatment of non-small cell lung cancer. Competition In addition to Janssen Diagnostics, LLC and Atossa Genetics, the company’s competitors include public companies such as Alere (Adnagen) and Illumina, as well as companies, including Apocell, EPIC Sciences, Clearbridge Biomedics, Cynvenio Biosystems, Fluxion Biosciences, RareCells, ScreenCell and Silicon Biosystems. History Biocept, Inc. was founded in 1997 in California.
(BIOC:Consolidated Issue listed on NASDAQ Capital Market)
5810 Nancy Ridge Drive
San Diego, CA 92121
|Atossa Genetics Inc||$1.91 USD||+0.13|
|Fluidigm Corp||$42.85 USD||+2.53|
|Illumina Inc||$187.62 USD||+0.45|
|Laboratory Corp of America Holdings||$127.28 USD||+0.13|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.